# Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1

> **NCT02705534** · PHASE3 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 50 (actual)

## Conditions studied

- Hepatitis C
- Cirrhosis

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Ledipasvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02705534
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02705534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02705534, "Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02705534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*